See more : EssilorLuxottica Société anonyme (ESLOY) Income Statement Analysis – Financial Results
Complete financial analysis of Anebulo Pharmaceuticals, Inc. (ANEB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anebulo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sunstone Development Co., Ltd. (603612.SS) Income Statement Analysis – Financial Results
- Jhen Vei Electronic Co., Ltd. (3520.TWO) Income Statement Analysis – Financial Results
- VIA Pharmaceuticals, Inc. (VIAP) Income Statement Analysis – Financial Results
- Porvair plc (PRV.L) Income Statement Analysis – Financial Results
- Sio Gene Therapies Inc. (SIOX) Income Statement Analysis – Financial Results
Anebulo Pharmaceuticals, Inc. (ANEB)
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.55M | 5.60M | 2.96M | 2.27M | 150.00K |
| General & Administrative | 4.76M | 6.18M | 3.87M | 1.34M | 140.11K |
| Selling & Marketing | 4.80K | 0.00 | 0.00 | 0.00 | 23.21K |
| SG&A | 4.76M | 6.18M | 3.87M | 1.34M | 23.35K |
| Other Expenses | 0.00 | -41.15K | -1.78K | -1.34K | 0.00 |
| Operating Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Cost & Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Interest Income | 97.79K | 92.41K | 7.33K | 1.02K | 7.72 |
| Interest Expense | 0.00 | 0.00 | 7.33K | 11.77K | 1.29K |
| Depreciation & Amortization | 258.28K | 11.78M | 6.83M | 3.61M | 1.04M |
| EBITDA | -8.05M | -11.78M | 5.56K | -30.24M | -173.35K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -11.78M | -6.83M | -3.61M | -173.35K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 107.05K | 51.26K | 5.56K | -26.64M | -1.29K |
| Income Before Tax | -8.20M | -11.73M | -6.83M | -30.25M | -174.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -104.19K | -12.89K | 10.75K | -1.04K |
| Net Income | -8.20M | -11.73M | -6.81M | -30.26M | -174.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| EPS Diluted | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Weighted Avg Shares Out | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
| Weighted Avg Shares Out (Dil) | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
7 Pot Stocks That Lit Up the News Cycle This Week
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
A Week's Worth of Actionable Cannabis Stock News
U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week
Source: https://incomestatements.info
Category: Stock Reports